Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus
- First Online:
- Cite this article as:
- Scott, L.J., Burness, C.B. & McCormack, P.L. BioDrugs (2012) 26: 195. doi:10.2165/11209060-000000000-00000
Belimumab (Benlysta ®), a fully human recombinant IgG1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells, is indicated for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite receiving standard therapy. In multinational trials, significantly more belimumab recipients than placebo recipients achieved an SLE Responder Index response at 52 weeks.